Price
$156.60+123%1Y
1M+0.49%1Y+123%
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageValue21
Quality67
Momentum80
Growth-
What they do
We are a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have significant unmet medical need such as (i) Geographic Atrophy (GA), the late atrophic (“dry”) form of age-related macular degeneration (AMD), and (ii) Stargardt disease type 1 (STGD1). Both GA and STGD1 cause progressive loss of vision leading to permanent blindness in almost all cases.
In the company’s own words · 20-F filed Mar 31, 2026 · SEC EDGAR
P/E (TTM)-
Market Cap$5.86B
1Y Return+123%
5Y Return-
Raw charts
5 series · TTMAs reported to the SEC, without any scoring.